Purdue Pharma LP — Patent Portfolio
1 drug with active patents · 79 active patents · 0 expired · 0 biologics with BPCIA exclusivity
Verdict Purdue Pharma LP's patent portfolio is vulnerable, with a significant cliff year in 2026 and $800 million in revenue at risk.
Portfolio overview Purdue Pharma LP has a total of 18 drugs in its portfolio, with 1 drug having patents and 79 total US patents, all of which are active. The average vulnerability score is 71, indicating a high level of vulnerability. The company has 0 ironclad patents and 51 vulnerable patents, with no biologics in its portfolio.
Cliff calendar In 2026, 1 drug will lose exclusivity, including Subutex. This marks a significant cliff year for the company, with a substantial loss of revenue.
Most exposed drugs The top drug facing near-term loss of exclusivity is Subutex, with an earliest active patent expiry date of 2026-07-31, an average vulnerability score of 71, and annual revenue of $800 million. This drug is particularly exposed, with a high vulnerability score and significant revenue at risk.
Biologic exclusivity Purdue Pharma LP has no biologics in its portfolio, and therefore does not have any biologic exclusivity.
Strategic implications The company faces a total of $800 million in revenue at risk over the next 5 years. To mitigate this risk, the company may consider lifecycle moves such as subQ switches, label extensions, or combination filings to extend the life of its patents and maintain revenue.
Loss of exclusivity calendar · next 12 years
Drugs facing US patent or BPCIA biologic exclusivity loss per year. Click any year to see the broader cliff calendar for the industry.
Patent estate by drug
Subutex (BUPRENORPHINE)
Cliff 2026 · 0y-
US8236755
Vuln 88
2026-07-31
This patent protects a pre-formulation for opioid depot formulations that dissolves or disperses an opioid bioactive agent, such as Subutex, in a mixture of neutral diacyl lipids, …
-
US8236755
Vuln 88
2026-07-31
This patent protects a pre-formulation for opioid depot formulations that dissolves or disperses an opioid bioactive agent, such as Subutex, in a mixture of neutral diacyl lipids, …
-
US8236755
Vuln 88
2026-07-31
This patent protects a method of using pre-formulations that contain an opioid bioactive agent, such as Subutex, to form a liquid crystalline phase structure upon contact with an a…
Patent classification breakdown · active patents
By US patent type. Method-of-use patents are most vulnerable to design-around; composition-of-matter patents are the strongest protection.
- Method of Use 70 patents
- Formulation 9 patents
Sources
- FDA Orange Book — small-molecule patents listed against approved NDAs.
- FDA Purple Book — biologic BPCIA 12-year reference product exclusivity.
- USPTO Patent Public Search — title, abstract, claim text grounding.
- AI summaries generated by Drug Landscape, grounded in source claim text.
Patent term extensions (PTR, SPC, pediatric exclusivity) may shift effective expiry. Not legal advice.
Track Purdue Pharma LP's patent estate
Daily alerts when vulnerability scores shift, patents expire, or IPRs are filed. Free tier: 3 watches. Pro tier (£199/mo): 50 watches + daily AI Pharma IP Brief.
↓ CSV export